new anticoagulant strategies in st elevation myocardial infarction: trials and clinical implications

Clicks: 129
ID: 251697
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #31 of 44 articles by views in jurnal pengajaran mipa

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Conor J McCann, Ian BA MenownCraigavon Cardiac Centre, Craigavon Area Hospital, Craigavon, Northern Ireland, UKAbstract: New data have re-established the importance of anticoagulation of patients with ST segment elevation myocardial infarction (STEMI), both as an adjuvant to reperfusion therapy or in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be superior to conventional unfractionated heparin. This article summarizes current understanding of the underlying pathophysiology of STEMI and provides a comprehensive review of emerging trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin inhibitors in this setting.Keywords: myocardial infarction, treatment, anticoagulants
Reference Key
mccann2008vascularnew Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Conor J McCann;Ian BA Menown
Journal jurnal pengajaran mipa
Year 2008
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.